Download full-text PDF |
Source |
|---|
Publication Analysis
Top Keywords
Similar Publications
Presentation and Surgical Outcomes of Primary Hyperparathyroidism After Radioactive Iodine Therapy.
J Surg Res
January 2025
Department of Surgery, Washington University School of Medicine, Saint Louis, Missouri.
Background: Radioactive iodine (RAI) is a common treatment for various thyroid diseases. Previous studies have suggested susceptibility of parathyroid glands to the mutagenic effect of RAI and the development of primary hyperparathyroidism (PHPT). We tested the possible link between prior RAI treatment, disease presentation, and treatment outcomes.
View Article and Find Full Text PDFChemogenetic modulation of parathyroid hormone secretion alleviates osteoporosis in ovariectomized rats.
Biochem Biophys Res Commun
January 2025
Guangdong Provincial Key Laboratory of Brain Connectome and Behavior, Shenzhen-Hong Kong Institute of Brain Science, Shenzhen Institutes of Advanced Technology, Chinese Academy of Sciences, Shenzhen, 518055, China; CAS Key Laboratory of Brain Connectome and Manipulation, The Brain Cognition and Brain Disease Institute, Shenzhen Institutes of Advanced Technology, Chinese Academy of Sciences, Shenzhen, 518055, China; University of Chinese Academy of Sciences, Beijing, 100049, China. Electronic address:
Parathyroid hormone (PTH) is critical for regulating calcium and phosphate homeostasis, and its dysregulation contributes to osteoporosis. Current methods for precise control of PTH secretion are limited. This study explores chemogenetic tools to regulate PTH secretion in parathyroid chief cells via Gq/Gi signaling.
View Article and Find Full Text PDFCase report: Prolonged and severe hungry bone syndrome after parathyroidectomy in X-linked hypophosphatemia.
Front Endocrinol (Lausanne)
January 2025
Department of Experimental Medicine, Sapienza University of Rome, Rome, Italy.
Tertiary hyperparathyroidism is characterized by hypercalcemia resulting from autonomous parathyroid hormone production and usually occurs after a prolonged period of secondary hyperparathyroidism. This condition can be a complication of X-linked hypophosphatemia (XLH), a rare genetic disease characterized by renal phosphate loss and consequent hypophosphatemia. Parathyroidectomy is considered the first-line therapy but surgical intervention can be complicated by hungry bone syndrome.
View Article and Find Full Text PDFSuccessful treatment of adult cherubism with a 60 mg denosumab 6-monthly regimen.
JBMR Plus
February 2025
Department of Diabetes and Endocrinology, Royal Melbourne Hospital, Melbourne, VIC 3050, Australia.
Cherubism is a rare autosomal dominant skeletal dysplasia, affecting the maxilla and/or mandible. The condition typically has childhood onset, followed by progression until puberty, with subsequent regression. Cherubism lesions share histological features with giant cell tumor of bone, where high-dose monthly denosumab is an effective medical treatment.
View Article and Find Full Text PDFUnlocking the mysteries of n-oxPTH: implications for CKD patients.
Front Endocrinol (Lausanne)
January 2025
Department of Nephrology, Henan Key Laboratory of Kidney Disease and Immunology, Henan Provincial People's Hospital, Zhengzhou, Henan, China.
Parathyroid hormone (PTH) is a pivotal hormone that regulates serum calcium and phosphate and is closely associated with higher risk of cardiovascular disease and mortality in patients with chronic kidney disease (CKD). PTH can undergo oxidation at methionine 8 and methionine 18 of the molecule. This oxidation process leads to a lower binding affinity to the PTH receptor due to molecular refolding, particularly for PTH oxidized at methionine 8.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!